Another study developed by this group, showed, using an in vivo ATM−/− mouse model, that RAD52 knockout seems to confer a longer latency period in T-cell lymphoma development, as well as an increase lifespan and decrease of tumor incidence when compared with the RAD52 wildtype model [55]. The gene discussed is RAD52; the disease is T-cell non-Hodgkin lymphoma.